Fringe therapy may help heart patients, study finds

March 29, 2013 by Amina Khan

A treatment that removes heavy metals from the body has long been touted as an alternative therapy to combat hardening arteries. Now a 10-year, $31 million clinical trial has found that chelation therapy does help heart attack patients slightly reduce their risk of serious heart problems - but not enough for the researchers to encourage mainstream cardiologists to offer it to their patients.

The trial revealed a very modest benefit for patients who took rather than a placebo, according to results published Wednesday in the Journal of the American Medical Association.

The findings came in for harsh criticism by other experts who worried that the results might encourage patients to take up a still unproven and potentially dangerous treatment.

"It's a type of medical quackery that has been around for many decades," said Dr. Steven Nissen, chair of at the Cleveland Clinic in Ohio.

Chelation therapy was introduced around as an antidote against an arsenic-based poison gas called Lewisite. The drug tested in the JAMA study - called ethylenediamine-tetraacetic acid, or EDTA - was used to treat lead poisoning in Navy personnel who repainted ships' hulls.

About 50 years ago, it came into vogue as an apparent way to remove mineral-rich deposits of plaque that can cause arteries to harden in a condition known as atherosclerosis.

Though still on the fringe, chelation therapy has been gaining traction: A National Center for Health Statistics report estimated that 111,000 patients had the expensive, time-consuming therapy in 2007 - a 68 percent jump from 2002. Patients clearly needed more information about this unproven treatment, said Dr. Judith Hochman, a cardiologist at New York University who was not involved in the study.

"There was an imperative to study it," Hochman said.

The National Center for and the National Heart, Lung and Blood Institute - two branches of the National Institutes of Health - agreed to fund it. Researchers from 134 facilities agreed to administer a cocktail comprising disodium EDTA, vitamins and electrolytes or a placebo to 1,708 patients who were at least 50 years old and had suffered a at least six weeks earlier. The 40 infusions were spread out over more than a year.

The researchers found that chelation did reduce patients' overall risk of heart problems, such as stroke and angina requiring hospitalization. Chelation patients' heart attack rate was 6 percent, compared with 8 percent for those on the placebo.

The strongest effect was seen with procedures to reopen the coronary artery: 15 percent of chelation patients needed them, compared with 18 percent of patients who got the placebo treatment. The difference was small, but it was just enough to be statistically significant, said Dr. Gervasio Lamas, the Columbia University cardiologist who led the study.

"I can't overemphasize how unexpected these results were," he said.

But the clinical trial was beset by a host of problems, said Nissen, who wrote an editorial in JAMA that was deeply critical of the study. Many of the patients dropped out of the trial, thus weakening the results, he said. What's more, some of the patients were treated in alternative medicine centers that sold unproven remedies such as aromatherapy and crystal therapy.

"How do you get good research done at places like that?" Nissen said. "I think you don't."

In addition, the Office for Human Research Protections in the Department of Health and Human Services launched an investigation, mentioning - among several other concerns - that a few researchers had been involved in insurance fraud and three were convicted felons.

Lamas said all researchers were thoroughly trained for their duties, whether they were doctors experienced in clinical trials or practitioners with expertise in chelation treatments. He also said some were bound to drop out of a study that was so time-consuming. (Each infusion lasted several hours.)

JAMA Editor in Chief Howard Bauchner said the study was put through the wringer before it was published, with the results vetted by a team of cardiologists, statisticians and other researchers. It deserved to be published regardless of negative attitudes toward the paper, he said.

But the findings are far from definitive, Hochman said: "The therapy's not ready for prime time."

Dr. Harlan Krumholz, a Yale University cardiologist who was not involved in the study, said that any apparent benefits to chelation would be hard for physicians to swallow.

"A lot of people thought this would be a good study because it would be a chance to disprove a therapy that had little support among mainstream academics," Krumholz explained. "It's a terrific group of investigators who've addressed an interesting question, who've come up with a surprising result that nobody knows what to do with."

Explore further: Study: Mega vitamins won't help after heart attack, chelation treatment might

Related Stories

Study: Mega vitamins won't help after heart attack, chelation treatment might

March 11, 2013
(HealthDay)—There's mixed news from a much-anticipated clinical trial for people who've suffered a heart attack: While a study found that daily high doses of vitamins and minerals did nothing to improve patient outcomes, ...

Chelation therapy doesn't alter quality of life in heart attack patients

November 5, 2012
Chelation therapy didn't change the ability to perform daily tasks or impact the emotional wellbeing of patients who previously suffered a heart attack, according to late-breaking clinical trial research presented at the ...

Alternative therapy produces intriguing results in some heart patients but many questions remain

November 5, 2012
Heart attack  patients given weekly infusions of chemicals used for chelation therapy had fewer cardiovascular events than those who received identical appearing placebo infusions, according to late-breaking clinical trial ...

High-dose oral vitamins, minerals do not reduce recurrent cardiac events in heart attack patients

March 12, 2013
Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's ...

Chelation therapy may result in small reduction of risk of CV events

March 26, 2013
Although chelation therapy with the drug disodium EDTA has been used for many years with limited evidence of efficacy for the treatment of coronary disease, a randomized trial that included patients with a prior heart attack ...

Recommended for you

Five vascular diseases linked to one common genetic variant

July 27, 2017
Genome-wide association studies have implicated a common genetic variant in chromosome 6p24 in coronary artery disease, as well as four other vascular diseases: migraine headache, cervical artery dissection, fibromuscular ...

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.